United States securities and exchange commission logo





                              July 14, 2023

       Hamid Erfanian
       Chief Executive Officer
       ENZO BIOCHEM INC
       81 Executive Blvd., Suite 3
       Farmingdale, New York 11735

                                                        Re: ENZO BIOCHEM INC
                                                            Amendment No. 1 to
Registration Statement on Form S-3
                                                            Filed July 10, 2023
                                                            File No. 333-272727

       Dear Hamid Erfanian:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our June
28, 2023 letter.

       Amendment No. 1 to Registration Statement on Form S-3

       Cover Page

   1.                                                   We note your amended
disclosure in response to comments 1 and 2, including that the
                                                        occurrence of an event
of default, including failing to consummate the asset sale, may
                                                        result in the
acceleration of the your obligations under the Debentures, and if this were to
                                                        occur, you may neither
have sufficient cash on hand nor have access to liquidity to be able
                                                        to repay such
obligations, which could result in you pursuing, among other options,
                                                        bankruptcy and
liquidation. Please amend your disclosure to clarify the impact on equity
                                                        holders if you were to
file for bankruptcy, including whether equity holders could expect
                                                        any recovery in
bankruptcy.
 Hamid Erfanian
ENZO BIOCHEM INC
July 14, 2023
Page 2

       Please contact Jessica Ansart at 202-551-4511 or Katherine Bagley at
202-551-2545 with
any questions.



                                                         Sincerely,

FirstName LastNameHamid Erfanian                         Division of
Corporation Finance
                                                         Office of Industrial
Applications and
Comapany NameENZO BIOCHEM INC
                                                         Services
July 14, 2023 Page 2
cc:       Dan Woodard
FirstName LastName